| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 May 2025 | 20 May 2025 |
| Pharmaids Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2025. The Board of Directors of the Company have approved the Audited Financial Results for the Quarter and Year ended March 31st 2025 at their meeting held on May 23, 2025. (As per BSE Announcement Dated on 23/05/2025) | ||
| Board Meeting | 12 Feb 2025 | 7 Feb 2025 |
| PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve the unaudited Financial results (Standalone and Consolidated) for the quarter and nine months ended December 31 2024. This is to inform you that Board of Directors in their meeting held today i.e. February 12, 2025 considered and approved the re-appointment of Mr.Venu Madhava Kaparthy (DIN: 00021699) as Whole Time Director designated as Executive Director of the Company and Ms.Mini Manikantan (DIN: 09663184) as Whole Time Director designated as Executive Director of the Company Subject to approval of the members of the Company. Unaudited Financial Results For The Quarter And Nine Months Ended 31st December 2024 (As Per BSE Announcement dated on 12.02.2025) | ||
| Board Meeting | 13 Nov 2024 | 7 Nov 2024 |
| PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and half year ended 30th September 2024. Financial Results for the Quarter and Half year ended September 30, 2024 (As Per BSE Announcement Dated on: 13/11/2024) | ||
| Board Meeting | 28 Aug 2024 | 20 Aug 2024 |
| PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/08/2024 inter alia to consider and approve the Audited Financial Statements (Standalone & Consolidated) for the year ended 31st March 2024 the Directors Report for the year ended 31st March 2024 Notice of 35th Annual General Meeting(AGM)and other AGM related matters. Outcome of the Board Meeting held on 28th August 2024, for approval of Annual Financial Statements for the financial year 2023-24 and AGM related matters. (As per BSE Announcement Dated on 28/08/2024) | ||
| Board Meeting | 13 Aug 2024 | 5 Aug 2024 |
| PHARMAIDS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve the Unaudited Financial Results (Standalone & Consolidated) for the quarter and three months ended 30th June 2024. Financial Results (Standalone & Consolidated) for the quarter and three months ended 30th June 2024. Intimation of Appointment of Mr. Prasanna Subramanya Bhat (Membership No. A48828) as Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company with effect from 14th August 2024. (As Per BSE Announcement dated on 13.08.2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.